The global atrial fibrillation treatment market, valued at USD 23.06 billion in 2023, is anticipated to reach USD 37.42 billion by 2033, with a compound annual growth rate (CAGR) of 5.2% over the forecast period.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5120
Atrial Fibrillation Treatment Market Insight Highlights:
- Atrial fibrillation treatment is gaining traction! The market surged to USD 23.06 billion in 2023.
- It’s projected to hit a healthy USD 37.42 billion by 2033.
- It is estimated to register a 5.2% CAGR over the forecast period.
- Catheter ablation leads the charge, holding a dominant 54% market share in 2023 and showcasing its effectiveness in controlling irregular heartbeats.
- Catheter ablation is also set to be the fastest-growing segment, further solidifying its dominance in the AFib market.
The National Institute of Health says atrial fibrillation is on the rise globally, especially with age. They predict that by 2050, the number of people with this condition could double or triple. This highlights the urgent need for better treatment options as the prevalence increases.
Heart and blood vessel diseases, known as cardiovascular diseases (CVDs), are increasingly prevalent, causing around 17.9 million deaths globally each year. These conditions encompass heart attacks, strokes, atrial fibrillation, and others. Heart attacks and strokes make up over 80% of CVD deaths, with one-third happening before age 70.
For instance,
- In 2021, the World Heart Federation estimates that Heart diseases, also known as cardiovascular diseases (CVDs), are still the main reason why people die worldwide, causing around 20.5 million deaths in the year 2021.
- In 2021, the United States saw the highest number of heart transplants ever, with 3,817 performed. California, Texas, New York, and Florida had the most heart transplant surgeries, with California leading at 529, followed by Texas with 359, New York with 307, and Florida with 263.
Atrial fibrillation is a common problem with the heart’s rhythm. It happens when the upper chambers of the heart don’t beat regularly. Instead, they quiver or shake. This can make it hard for the heart to pump blood properly and can raise the chance of blood clots forming in the heart. A few things can cause atrial fibrillation, like having high blood pressure, heart disease, being overweight, having sleep problems like sleep apnea, or drinking too much alcohol. Doctors usually find atrial fibrillation by doing a test called an electrocardiogram (ECG), which checks for irregular heartbeats. It’s super important to catch atrial fibrillation early because it can lead to severe problems like strokes, heart failure, and other heart issues. Treating atrial fibrillation quickly with medications like blood thinners to stop clots from forming or procedures like catheter ablation to fix the heart’s rhythm can really help manage atrial fibrillation and lower the risks. The market for treating atrial fibrillation has been growing a lot because more people are becoming aware of it, technology in medicine is getting better, and there are more risk factors like getting older and changing lifestyle habits. So, scientists are constantly working on new ways to help people with atrial fibrillation have better outcomes.
Recent Developments
- In February 2023, Abbott got the green light from the European Union and the US FDA for its TactiFlex Ablation Catheter and Sensor Enabled products. These cool catheters are designed to treat abnormal heart rhythms, like atrial fibrillation. They have a bendy tip and can sense how much force they put on the heart. The FlexAbility Ablation Catheter and Sensor Enabled got extra approval from the US FDA, meaning it can now be used to treat patients with complicated heart issues.
- In November 2021, Medtronic, India, invented the Arctic Front Cardiac Cryoablation Catheter System. This tool helps treat atrial fibrillation by targeting a part of the heart and stopping abnormal electrical signals. These new technologies and treatments are expected to improve healthcare for patients with heart problems, leading to better outcomes.
Atrial Fibrillation Treatment Market Companies
- Boston Scientific Corporation
- Johnson & Johnson Med Tech
- Pfizer
- Bristol Myers Squibb
- Boehringer Ingelheim
- Bayer
- Novartis
- AtriCure, Inc.
- Medtronic
- Abbott
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/atrial-fibrillation-treatment-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5120
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare